Cancer – ACNS1721: Phase 2 Study of Veliparib and Local Irradiation, Followed by Maintenance Veliparib and Temozolomide, in Patients with Newly Diagnosed High-Grade Glioma Without H3 K27M or BRAFV600E Mutations
Condition or Therapy:
Anaplastic astrocytoma, BRAF V600, glioblastoma, H3 K27M Negative, Malignant glioma
What is the goal of this study?
The goal of this study is to determine whether veliparib (ABT-888), when added to radiotherapy and temozolomide, is efficacious for the treatment of patients with newly diagnosed high-grade glioma (HGG) whose tumors molecular profile are wild-type for H3 K27M, BRAF, and IDH1/2.
Who can join the study?
This study might be a good fit for children and young adults who:
- Are 3 to 25 years old
- Are newly diagnosed with high-grade glioma (such as anaplastic astrocytoma or glioblastoma) and have negative results for BRAFV600 mutation by next generation sequencing (NGS)
What will happen if my child takes part in this study?
You can read more about this study on clinicaltrials.gov.
Who can I contact for more information?
To learn more, call 206-987-2106 or send us an email.